Moreover, no group of patients with pathogenic biallelic variants in PRKN and PINK1 without l-Dopa treatment was available, preventing deeper insight into the effects of dopaminergic medication on the metabolome in this group of patients with PD. This evidence concerns the gene PINK1 and Parkinson disease.